Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Collaborative Research and Development Grants

University of British Columbia

$57,600.00

Microbial metabolic engineering for cannabinoid biosynthesis

FY 2018-19

Summary
Marijuana ranks among history's most popular remedies for alleviating pain, and thanks to modern science, we now know that the plant's therapeutic effects can be ascribed to 60 unique chemical compounds that it synthesizes. Called the 'cannabinoids', these molecules exert their influence by activating a unique class of cellular receptors that then influence the perception of pain in the brain, as well as organs such as the liver, pancreas and the eyes. Consequently, we are proposing to leverage the interaction between cannabinoids and their receptors to identify new drugs for the treatment of Huntington's disease, a brain disorder that has a surprising connection to the receptors under investigation. Additionally, since sourcing cannabinoids from plant sources presents severe technological and logistical challenges, we will also develop a manufacturing process that employs genetically engineered microorganisms for the production of these molecules. The use of microorganisms for the manufacture of pharmaceutical products is a revolutionary advance. We will be jointly undertaking these research & development activities with InMed Pharmaceuticals Inc., a Canadian biopharmaceuticals company. The success of this project will represent a major achievement for the emerging Canadian biopharmaceutical industry, establish InMed Pharmaceuticals, a young, homegrown enterprise, as a global leader in cannabinoid therapeutics, and provide immense social and strategic benefit to Canada.
Program
Collaborative Research and Development Grants
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
522967-2017
Name nom
Yadav, VikramadityaGanapati
Department département
Chemical and Biological Engineering
Organization id
2
Institution établissement
University of British Columbia
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2018
Competition year année de concours
2017
Award amount
57600
Program id
CRDPJ
Program name en
Collaborative Research and Development Grants
Program name fr
Subventions de recherche et développement coopérative
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
1802
Research subject group en
Chemical engineering
Research subject group fr
Génie chimique
Research subject en
Biochemical engineering
Research subject fr
Génie biochimique
Partie
1
Nb partie
1
Application title
Microbial metabolic engineering for cannabinoid biosynthesis
Keyword
NSERC
Application summary
Marijuana ranks among history's most popular remedies for alleviating pain, and thanks to modern science, we now know that the plant's therapeutic effects can be ascribed to 60 unique chemical compounds that it synthesizes. Called the 'cannabinoids', these molecules exert their influence by activating a unique class of cellular receptors that then influence the perception of pain in the brain, as well as organs such as the liver, pancreas and the eyes. Consequently, we are proposing to leverage the interaction between cannabinoids and their receptors to identify new drugs for the treatment of Huntington's disease, a brain disorder that has a surprising connection to the receptors under investigation. Additionally, since sourcing cannabinoids from plant sources presents severe technological and logistical challenges, we will also develop a manufacturing process that employs genetically engineered microorganisms for the production of these molecules. The use of microorganisms for the manufacture of pharmaceutical products is a revolutionary advance. We will be jointly undertaking these research & development activities with InMed Pharmaceuticals Inc., a Canadian biopharmaceuticals company. The success of this project will represent a major achievement for the emerging Canadian biopharmaceutical industry, establish InMed Pharmaceuticals, a young, homegrown enterprise, as a global leader in cannabinoid therapeutics, and provide immense social and strategic benefit to Canada.
University of British Columbia - $57,600 Grant (2018-… | Canada Spends